Inhibition of dopamine-b-hydroxylase in manic patients. A clinical trial and fusaric acid.
D001714:Bipolar Disorder / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000378:metabolism; D004299:Dopamine beta-Hydroxylase / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D010848:Picolinic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D011599:Psychopathology; D012075:Remission, Spontaneous
D004791:Enzyme Inhibitors; D010848:Picolinic Acids; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D004299:Dopamine beta-Hydroxylase; D004298:Dopamine; D006719:Homovanillic Acid